Your browser doesn't support javascript.
Prevention of Sars-Cov-2 Transmission During a Large, Live, Indoor Gathering: The Noninferiority Randomised-Controlled Spring Trial (preprint)
ssrn; 2021.
Preprint in English | PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.3905915
ABSTRACT

Background:

Mass indoor gatherings were banned in early 2020 to prevent SARS-CoV-2 spread. We aimed to assess, under controlled conditions, whether systematic antigen-screening within 3 days, medical mask-wearing and optimized ventilation could prevent SARS-CoV-2 spread during a large, indoor gathering without physical distancing.

Methods:

The non-inferiority, prospective, open-label, randomized (21)-controlled SPRING trial was conducted on May 29, 2021 in Paris, France. Participants, 18–45 years old, had no comorbidities, COVID-19 symptoms and recent case contact, and a negative rapid antigen diagnostic test within 3 days before the concert. Participants were randomly allocated to the experimental arm (attendees) or to the control arm (non-attendees). The primary outcome measure was the number of SARS-CoV-2–positive RT-PCR on self-collected saliva 7 days (D7) post-gathering. An artificial intelligence tool analyzing anonymised, continuous video-capture data evaluated participants’ mask-wearing compliance. This trial is registered with ClinicalTrials.gov, NCT04872075.

Findings:

Among 6678 randomized participants (median age 28 years; 59% women), 88% of each group complied with follow-up requirements. The D7 RT-PCR was positive for eight of the 3917 attendees (observed incidence, 0.20%; 95% Confidence Interval [CI], 0.09 to 0.40) and 3 of the 1,947 non-attendees (0.15%; 0.03 to 0.45) (absolute difference, 95%CI, –0.26% to +0.28%), findings that met the non-inferiority criterion (margin <0.35%) for the primary endpoint. Global facemask-wearing compliance (i.e., covering nose and mouth) was estimated at 91.4% (95%CI, 87.7 to 95.4).

Interpretation:

Participation in a large, indoor, live gathering without physical distancing was not associated with increased SARS-CoV-2transmission risk, provided a comprehensive preventive intervention was implemented.Trial Registration This study was registered on ClinicalTrials.gov (NCT04872075).

Funding:

French Ministry of HealthDeclaration of Interest All authors declare no competing interestsEthical Approval The trial protocol was approved by the Scientific Ethics Committee of the Sud-Ouest and Outremer Regions of France and the French Data-Protection Agency
Subject(s)

Full text: Available Collection: Preprints Database: PREPRINT-SSRN Main subject: COVID-19 Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Preprints Database: PREPRINT-SSRN Main subject: COVID-19 Language: English Year: 2021 Document Type: Preprint